Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The highly potent botulinum neurotoxin serotype A (BoNT/A) inhibits neurotransmitter release at neuromuscular junctions resulting in flaccid muscle paralysis, respiratory arrest and death. In order to reach their neuronal cell targets, BoNT/A must cross epithelial cell barriers lining the intestines and airways. The toxin is produced as a large protein complex comprised of the neurotoxin and non-toxic neurotoxin-associated proteins (NAPs). Although NAPs are known to protect the toxin from harsh environments, their role in the movement of BoNT/A across epithelial barriers has not been fully characterized. In the current study, movement of the toxin across epithelial cells was examined macroscopically using a sensitive near infrared fluorescence transcytosis assay and microscopically using fluorescently labeled toxin and confocal microscopy. The studies show that the BoNT/A complex internalizes more rapidly than the pure toxin. The studies also show that one NAP protein, hemaglutinin 33 (Hn33), enhanced both the binding and movement of a deactivated recombinant botulinum neurotoxin A (DrBoNT) across epithelial cell monolayers and that the toxin associates with Hn33 on the cell surface. Collectively, the data demonstrate that, in addition to their protective role, NAPs and Hn33 play an important role in BoNT/A intoxication.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033393PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199524PLOS

Publication Analysis

Top Keywords

botulinum neurotoxin
12
epithelial cell
8
toxin
7
bont/a
5
role
4
role critical
4
critical elements
4
elements botulinum
4
neurotoxin
4
neurotoxin complex
4

Similar Publications

Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.

Methods: This is an open-label, nonrandomized controlled trial.

View Article and Find Full Text PDF

Unlabelled: Drooling is a common problem in children with neurodisability, and refractory cases may require surgery. Our aim was to assess whether a child's response to salivary botulinum toxin injections would predict success or failure from subsequent surgical intervention. Retrospective case note review of all children undergoing drooling surgery between 1st January 2007 and 31st December 2023 at the Royal Hospital for Children, Glasgow.

View Article and Find Full Text PDF

Perineural botulinum toxin in the management of post-traumatic headache: a case report.

Rev Esp Anestesiol Reanim (Engl Ed)

September 2025

Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.

Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).

View Article and Find Full Text PDF

Gut mucin fucosylation dictates the entry of botulinum toxin complexes.

bioRxiv

August 2025

Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa 920-8640, Japan.

Botulinum toxins (BoNTs) are the most potent known bacterial toxins. The BoNT complex from B-Okra (large progenitor toxin complex (L-PTC)/B, hyper-oral-toxic) exerts at least 80-fold higher oral toxicity in mice compared with that from serotype A1 (L-PTC/A, non-hyper-oral-toxic). Here, we showed that L-PTC/B was predominantly absorbed through enterocytes, whereas L-PTC/A targeted intestinal microfold cells.

View Article and Find Full Text PDF

Botulinum Neurotoxin Type A (BoNT-A) remains the cornerstone of glabellar frown line treatment, yet conventional low-dose, high-volume protocols often result in limited durability and imprecise diffusion. This study presents multiscale, in silico framework specifically designed to evaluate high-dose (60-80 Units), low-volume (≤0.045 mL/site) BoNT-A glabellar injection strategies across anatomically realistic conditions.

View Article and Find Full Text PDF